QR-1123

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameQR-1123
Drug Alias NameQR-1123IONIS-RHO-2.5RxION-357
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionRhodopsin P23H mutant protein expression inhibitors
TargetsRhodopsin
Therapy Area/IndicationsRetinitisRetinal DystrophiesRetinal Diseases +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesProqr Therapeutics NvProqr Therapeutics
Inactive CompaniesN/A
Active IndicationsRetinitisRetinal DystrophiesRetinal Diseases +[6] 
Inactive IndicationsEye Diseases

Other Information

ATC CodeN/A
Related LinksN/A